Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Chief Operations Officer | November 16, 2021 | November 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date November 16, 2021 · Filed November 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,097 |
Reported balance
After 2021-11-16 transaction · row 1
1 source rowRow 1 · 2021-11-16 · Sale · Disposed 3,332 · Balance 113,097 F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2019 Filed May 7, 2019 20:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-19-027981 · doc4.xml · derivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| May 06, 2019 Filed May 7, 2019 20:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $35.00 | $52,500.00 |
DisclosureSEC source: 0001209191-19-027981 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,498 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| May 06, 2019 Filed May 7, 2019 20:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-19-027981 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| April 03, 2019 Filed Apr 3, 2019 23:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 648 | $41.04 | $26,593.92 |
DisclosureSEC source: 0001209191-19-023491 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,498 F3 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-19-023491 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F4 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $39.96 | $59,940.00 |
DisclosureSEC source: 0001209191-19-023491 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,146 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.66 to $40.63. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-19-023491 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 21:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021443 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,146 F1 · shares: These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-19-017038 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F4 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 200 | $36.75 | $7,350.00 |
DisclosureSEC source: 0001209191-19-017038 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,146 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.66 to $36.84. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,300 | $36.04 | $46,852.00 |
DisclosureSEC source: 0001209191-19-017038 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,346 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.56 to $36.43. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-19-017038 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $38.47 | $0.00 |
DisclosureSEC source: 0001209191-19-008504 · doc4.xml · derivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-02-05 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008504 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,146 F2 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 2,212 | $38.47 | $85,095.64 |
DisclosureSEC source: 0001209191-19-008504 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,646 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 02, 2019 Filed Feb 1, 2019 23:49 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 500 | $38.44 | $19,220.00 |
DisclosureSEC source: 0001209191-19-006607 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.31 to $38.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 23:49 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-19-006607 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,500 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F4 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 23:49 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,000 | $37.80 | $37,800.00 |
DisclosureSEC source: 0001209191-19-006607 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,358 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.28 to $38.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 23:49 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-19-006607 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| February 01, 2019 Filed Apr 1, 2019 20:16 UTC Amendment | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 500 | $38.44 | $19,220.00 |
DisclosureSEC source: 0001209191-19-021971 · doc4a.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · date: This amendment is being filed solely to correct the date of sale. F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.31 to $38.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-19-000518 · doc4.xml · derivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $35.00 | $52,500.00 |
DisclosureSEC source: 0001209191-19-000518 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-19-000518 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 00:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-18-060680 · doc4.xml · derivative · entry 5 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F5 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 00:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 127 | $42.54 | $5,402.58 |
DisclosureSEC source: 0001209191-18-060680 · doc4.xml · nonDerivative · entry 4 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.49 to $42.66. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 00:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 400 | $41.97 | $16,788.00 |
DisclosureSEC source: 0001209191-18-060680 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,985 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.40 to $42.38. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 00:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 973 | $40.61 | $39,513.53 |
DisclosureSEC source: 0001209191-18-060680 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,385 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.30 to $41.28. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 00:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-18-060680 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-18-057055 · doc4.xml · derivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $35.00 | $52,500.00 |
DisclosureSEC source: 0001209191-18-057055 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-18-057055 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-18-053131 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,500 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F4 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 400 | $41.99 | $16,796.00 |
DisclosureSEC source: 0001209191-18-053131 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.75 to $42.21. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,100 | $41.02 | $45,122.00 |
DisclosureSEC source: 0001209191-18-053131 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,258 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.53 to $41.36. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-18-053131 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-18-049620 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F4 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 498 | $40.04 | $19,939.92 |
DisclosureSEC source: 0001209191-18-049620 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.75 to $40.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,002 | $39.16 | $39,238.32 |
DisclosureSEC source: 0001209191-18-049620 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,356 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.60 to $39.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-18-049620 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| August 01, 2018 Filed Aug 1, 2018 22:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-18-044804 · doc4.xml · derivative · entry 6 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,500 Underlying: Common Stock · 1,500 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F4 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| August 01, 2018 Filed Aug 1, 2018 22:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 100 | $40.40 | $4,040.00 |
DisclosureSEC source: 0001209191-18-044804 · doc4.xml · nonDerivative · entry 5 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| August 01, 2018 Filed Aug 1, 2018 22:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $39.05 | $11,715.00 |
DisclosureSEC source: 0001209191-18-044804 · doc4.xml · nonDerivative · entry 4 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,958 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.70 to $39.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 01, 2018 Filed Aug 1, 2018 22:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 100 | $37.65 | $3,765.00 |
DisclosureSEC source: 0001209191-18-044804 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,258 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| August 01, 2018 Filed Aug 1, 2018 22:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,000 | $37.09 | $37,090.00 |
DisclosureSEC source: 0001209191-18-044804 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,358 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.50 to $37.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 01, 2018 Filed Aug 1, 2018 22:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,500 | $20.40 | $30,600.00 |
DisclosureSEC source: 0001209191-18-044804 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| July 30, 2018 Filed Jul 31, 2018 21:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-18-044584 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 10,000 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F4 · derivative.exercise_date: 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service. Read SEC document |
| July 30, 2018 Filed Jul 31, 2018 21:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,900 | $36.37 | $69,103.00 |
DisclosureSEC source: 0001209191-18-044584 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.20 to $36.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 30, 2018 Filed Jul 31, 2018 21:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,100 | $35.64 | $288,684.00 |
DisclosureSEC source: 0001209191-18-044584 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,758 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.15 to $36.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 30, 2018 Filed Jul 31, 2018 21:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 10,000 | $20.40 | $204,000.00 |
DisclosureSEC source: 0001209191-18-044584 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018. Read SEC document |
| April 03, 2018 Filed Apr 4, 2018 20:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 642 | $36.25 | $23,272.50 |
DisclosureSEC source: 0001209191-18-023596 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.